SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
SK Hynix, Intel Discuss U.S. Memory Chip Production Deal 
Boeing, SPEEA Reach Tentative Four-Year Labor Deal 
China vs. NASA: The New Moon Race and What's at Stake by 2030 
Tabletop particle accelerator could transform medicine and materials science 
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026 
FDA Pilot Program Eases Rules for Nicotine Pouch Makers 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
Samsung Heavy Wins $1.22 Billion LNG Carrier and Tanker Deal 
Samsung, SK Hynix Reject KEPCO’s $18.7 Billion Power Funding Plan 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Bill Gates Warns Governments Are Unprepared for AI Disruption 
MediaTek Unveils 2nm Dimensity 9600 Pro AI Chip 
SpaceX Nasdaq 100 Weight Set to More Than Double 
SpaceX Delays Starship V3 Launch Ahead of Potential Record IPO 
NASA's Artemis II Crew Arrives in Florida for Historic Moon Mission 
Qualcomm Gains on $60B Amazon AI Chip Deal 
Add as a preferred source on Google
AstraZeneca's drug Imfinzi (NASDAQ: AZN) has received U.S. approval to treat adult patients with muscle-invasive bladder cancer, a significant advancement in cancer therapy. The approval allows Imfinzi to be used in combination with gemcitabine and cisplatin as a neoadjuvant treatment before surgery. After a procedure called radical cystectomy, Imfinzi will also serve as an adjuvant monotherapy.
This approval marks a major milestone for bladder cancer treatment. Clinical trials have demonstrated that the Imfinzi-based regimen can reduce the risk of death by 25% compared to the standard neoadjuvant chemotherapy followed by radical cystectomy alone. This offers new hope for patients suffering from this aggressive form of cancer.
Imfinzi’s approval for muscle-invasive bladder cancer strengthens AstraZeneca’s position in oncology and offers a promising option for those with limited treatment choices. The combination of Imfinzi with chemotherapy drugs like gemcitabine and cisplatin represents a breakthrough in improving survival rates for these patients.
With this approval, Imfinzi is poised to play a crucial role in the treatment landscape for muscle-invasive bladder cancer, providing doctors with a valuable tool to enhance patient outcomes. This development highlights the continued progress in oncology, particularly in addressing challenging cancers like bladder cancer.
By optimizing the use of Imfinzi, patients can now access a more effective treatment option that offers improved survival rates, marking a pivotal moment in cancer care.
